Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 11 to 20 of 65 total matches.

In Brief: A New Breast Cancer Indication for Sacituzumab Govitecan (Trodelvy) (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023  (Issue 1671)
platinum-based chemotherapy and a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1 ...
Sacituzumab govitecan-hziy (Trodelvy – Gilead) has been approved for treatment of unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in adults who received prior endocrine therapy and ≥2 additional systemic therapies for metastatic disease. It was previously approved for treatment-refractory metastatic triplenegative breast cancer and for treatment of locally advanced or metastatic urothelial cancer in adults who received platinum-based chemotherapy and a programmed death receptor-1...
Med Lett Drugs Ther. 2023 Mar 6;65(1671):e43-4   doi:10.58347/tml.2023.1671g |  Show IntroductionHide Introduction

In Brief: Fam-trastuzumab deruxtecan (Enhertu) for Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023  (Issue 1673)
cancer in patients who received prior chemotherapy for metastatic disease or who developed disease ...
Fam-trastuzumab deruxtecan-nxki (Enhertu – Daiichi Sankyo/AstraZeneca), which received accelerated approval by the FDA in 2019 for treatment of HER2-positive breast cancer based on its rate and duration of response,1 has been granted regular approval for treatment of adults with unresectable or metastatic HER2-positive breast cancer who received a prior anti-HER2-based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and developed recurrence during or within 6 months of completing treatment.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e60-1   doi:10.58347/tml.2023.1673f |  Show IntroductionHide Introduction

Tisotumab Vedotin (Tivdak) for Cervical Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024  (Issue 1705)
cancer that progressed on or after chemotherapy. It is the first antibody-drug conjugate to be approved ...
Tisotumab vedotin-tftv (Tivdak – Seagen/Genmab), a tissue factor-directed antibody and microtubule inhibitor conjugate, has received full approval from the FDA for treatment of recurrent or metastatic cervical cancer that progressed on or after chemotherapy. It is the first antibody-drug conjugate to be approved for treatment of cervical cancer. The drug received accelerated approval from the FDA in 2021 for the same indication.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e109-10   doi:10.58347/tml.2024.1705g |  Show IntroductionHide Introduction

Quizartinib (Vanflyta) for Acute Myeloid Leukemia (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023  (Issue 1687)
, and as maintenance monotherapy following consolidation chemotherapy in adults with FLT3 internal tandem duplication ...
The FDA has approved the oral kinase inhibitor quizartinib (Vanflyta – Daiichi Sankyo) for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy in adults with FLT3 internal tandem duplication (ITD)-positive, newly-diagnosed acute myeloid leukemia (AML).
Med Lett Drugs Ther. 2023 Oct 16;65(1687):e169-70   doi:10.58347/tml.2023.1687d |  Show IntroductionHide Introduction

Tebentafusp (Kimmtrak) for Uveal Melanoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024  (Issue 1705)
. Patients were randomized to receive tebentafusp or investigator-selected chemotherapy (pembrolizumab ...
The FDA has approved tebentafusp-tebn (Kimmtrak – Immunocore), a first-in-class bispecific gp100 peptide-HLA-directed CD3 T-cell engager, for treatment of HLA-A*02:01-positive unresectable or metastatic uveal melanoma in adults.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e107-8   doi:10.58347/tml.2024.1705f |  Show IntroductionHide Introduction

Sacituzumab Govitecan (Trodelvy) for Metastatic Triple-Negative Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021  (Issue 1617)
conjugate to become available in the US. Standard Treatment – Sequential single-agent chemotherapy ...
The FDA has approved sacituzumab govitecan-hziy (Trodelvy – Immunomedics), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with metastatic triple-negative breast cancer who have received ≥2 prior therapies for metastatic disease. It is the first Trop-2-directed antibody-drug conjugate to become available in the US.
Med Lett Drugs Ther. 2021 Feb 8;63(1617):e24-5 |  Show IntroductionHide Introduction

In Brief: A New Prostate Cancer Indication for Olaparib (Lynparza) (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023  (Issue 1679)
)-negative, high-risk early breast cancer who received prior neoadjuvant or adjuvant chemotherapy.1 It had ...
The oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza – AstraZeneca) has now been approved by the FDA for use in combination with abiraterone (Zytiga, and others) and either prednisone or prednisolone for treatment of adults with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib was previously approved by the FDA for treatment of adults with deleterious or suspected deleterious germline or somatic homologous recombinant repair (HRR) genemutated mCRPC who progressed on prior treatment with...
Med Lett Drugs Ther. 2023 Jun 26;65(1679):e106-7   doi:10.58347/tml.2023.1679g |  Show IntroductionHide Introduction

Amivantamab (Rybrevant) for Non-Small Cell Lung Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
chemotherapy. It is the first bispecific antibody to become available in the US for this indication ...
Amivantamab-vmjw (Rybrevant – Janssen), an EGFR-MET bispecific antibody, has received accelerated approval from the FDA for IV treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations in adults whose disease has progressed on or after platinum-based chemotherapy. It is the first bispecific antibody to become available in the US for this indication. Accelerated approval of the drug was based on the overall response rate and duration of response.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e184-5 |  Show IntroductionHide Introduction

Margetuximab (Margenza) for HER2-Positive Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022  (Issue 1664)
(Margenza – MacroGenics), a HER2/neu receptor antagonist, for use in combination with chemotherapy ...
The FDA has approved margetuximab-cmkb (Margenza – MacroGenics), a HER2/neu receptor antagonist, for use in combination with chemotherapy for treatment of metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in adults who received ≥2 prior anti-HER2 regimens, at least one of which was for metastatic disease.
Med Lett Drugs Ther. 2022 Nov 28;64(1664):e195-6 |  Show IntroductionHide Introduction

Mobocertinib (Exkivity) for Non-Small Cell Lung Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022  (Issue 1664)
insertion mutations in adults whose disease has progressed on or after platinum-based chemotherapy ...
Mobocertinib (Exkivity – Takeda), an oral kinase inhibitor, has received accelerated approval from the FDA for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations in adults whose disease has progressed on or after platinum-based chemotherapy. Accelerated approval was based on the overall response rate and duration of response. Mobocertinib is the second drug to become available in the US for this indication; the IV EGFR-MET bispecific antibody amivantamab (Rybrevant) was approved...
Med Lett Drugs Ther. 2022 Nov 28;64(1664):e197-8 |  Show IntroductionHide Introduction